Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03302416 · ClinicalTrials.gov registry record · Early Phase 1
CRF - Nociceptin Receptor Interactions
A Early Phase 1 study of Healthy, sponsored by University of Pittsburgh.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 19
- Enrollment target
- 1
- Study location
NCT03302416 is a Early Phase 1 study of Healthy that has completed, run by University of Pittsburgh. The registered enrollment target is 19 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03302416, a Early Phase 1 study of Healthy, has completed, sponsored by University of Pittsburgh.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 19 participants
- Enrollment target
- 1
- Study location
Study Summary
To determine if \[C-11\]NOP-1A receptor binding (VT) can be altered by an intravenous hydrocortisone (cortisol) challenge through CRF-NOP interactions
Conditions Studied
Interventions
- DRUG Hydrocortisone
- RADIATION [C-11]NOP-1A
Study Locations (1)
Pennsylvania
- University of Pittsburgh - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2016-06-01 |
| Est. Completion | 2019-06-01 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03302416
The ClinicalTrials.gov registry entry for NCT03302416 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (97% lower). The listed sponsor is University of Pittsburgh, which has 1,238 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 2 interventions - of which Hydrocortisone is the first listed.
NCT03302416 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT03302416 about?
NCT03302416 is a clinical study titled "CRF - Nociceptin Receptor Interactions". To determine if \[C-11\]NOP-1A receptor binding (VT) can be altered by an intravenous hydrocortisone (cortisol) challenge through CRF-NOP interactions
What is the current status of trial NCT03302416?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 19 participants. The study started on 2016-06-01. Estimated completion is 2019-06-01.
What conditions does trial NCT03302416 study?
This clinical trial studies the following conditions: Healthy.
What interventions are being tested in trial NCT03302416?
The interventions under investigation include: Hydrocortisone (DRUG), [C-11]NOP-1A (RADIATION).
Who is sponsoring clinical trial NCT03302416?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03302416 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Mapping Auricular Vagus Nerve Circuitry
RECRUITING · Early Phase 1
-
Saccharomyces Boulardii CNCM I-745 on Intestinal Barrier Function
RECRUITING · Early Phase 1
-
SV2A Density Cannabis Use Disorder
RECRUITING · Early Phase 1
-
CBD-Microglia PET Study
RECRUITING · Early Phase 1
-
Sex Disparities in Hypoxic Vasodilation and Impact of Obesity
RECRUITING · Early Phase 1
-
Positron Emission Tomography (PET) Contrast Agent Kinetics and Safety: [18F]-Fluoromannitol
RECRUITING · Early Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.